跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
XULTOPHY
Authorized
STANDARD
XULTOPHY
Novo Nordisk Canada Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
2c6f8c7e41b0b694
Company
Novo Nordisk Canada Inc
Type
Standard
Approval Details
Approval Id
2c6f8c7e41b0b694
Drug Approval Canada Name
XULTOPHY
Product Name
XULTOPHY
Status
Marketed
Status Date
2018-06-06
Original Market Date
2018-06-06
Din
02474875
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Schedule D , Prescription
Ahfs
68:20.06
Atc Original
A10AE56 INSULIN DEGLUDEC AND LIRAGLUTIDE
Atc Name
a 10 ae 56
Aig Number
0260170001
Company Name
Novo Nordisk Canada Inc
Company Address
101-2476 Argentia Road, Mississauga, Ontario, Canada, L5N 6M1
Active Ingredients
INSULIN DEGLUDEC
100 UNIT / ML
LIRAGLUTIDE
3.6 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
2c6f8c7e41b0b694
Type
Standard
Back to Health Canada Approvals
XULTOPHY - Health Canada Drug Approval Details